FDA ADVISERS REJECT MDMA FOR PTSD TREATMENT AMID CONCERNS
In a surprising turn of events, key FDA advisers voted against the approval of MDMA for treating PTSD, citing insufficient evidence of its efficacy and a poor risk-benefit ratio. The advisory committee expressed concerns about the trials’ ability to maintain blind conditions and the influence of participants’ expectations on the results. The FDA, while not bound by the committee’s decision, usually adheres to its advice, emphasizing the challenges of evaluating psychedelic drugs and their psychiatric applications. Lykos Therapeutics has developed a treatment involving MDMA alongside psychotherapy, suggesting that MDMA’s primary role is to facilitate openness during therapy sessions. Despite reports of significant improvement in PTSD symptoms in clinical trials, FDA scientists and the advisory committee raised issues about the lack of comprehensive safety data and potential biases due to participants’ prior MDMA use and other treatments sought during the trials. Concerns were also voiced about the variability in therapy quality, the training of therapists, and the need for stringent regulations to protect patients. As the FDA prepares to make a final decision, the debate underscores the complexities and potential of psychedelic-assisted therapies in psychiatric care. (Nature)
PHARMA GIANTS READY $1 TRILLION FOR BIOTECH INNOVATION
Pharmaceutical companies have accumulated a record $1 trillion to invest in biotech innovations, pending favorable conditions such as a potential reduction in Federal Reserve rates, reports Ernst & Young. Despite market predictions leaning towards stable short-term rates, the biotech sector could see a resurgence if financial pressures ease. This optimism is supported by the pharma industry’s need to innovate as $300 billion worth of products are nearing the end of their patent protections. Over the past two years, financial constraints have led to significant layoffs and restructurings within biotech firms, yet the sector continues to demonstrate robust innovation, with 80 new biopharma products approved by the FDA in 2023. This innovation is crucial as big pharma faces a “patent cliff,” and ongoing challenges such as the implementation of the IRA. Despite a downturn in venture funding and initial public offerings, partnerships have flourished, with pharma companies investing heavily in alliances to access new technologies with lower risk. The start of the year has also seen an uptick in mergers and acquisitions, signaling a potentially more active phase in deal-making. (Fierce Biotech)
If you’re enjoying the Daily Dose, sign up for the Daily Dose Newsletter and get the morning’s best science news from around the web delivered straight to your inbox? It’s easy like Sunday morning.
GRAYSON MURRAY’S DEATH IGNITES GOLF MENTAL HEALTH DEBATE
In January 2024, Grayson Murray triumphed at the Sony Open in Hawaii, marking a high point after battling depression and alcohol addiction. Despite his personal achievements and supportive family, Murray tragically died by suicide four months later at age 30. His death has sparked discussions about mental health support in individual sports like golf. Previously, Murray criticized the PGA Tour for inadequate mental health resources, although the tour later introduced well-being benefits and assistance programs. Renowned sports psychologist Dan Abrahams emphasized that golf, traditionally focused on performance psychology, must evolve to incorporate mental health and well-being support similar to team sports. He advocates for a “psychologically informed environment” at sports events to provide continuous access to mental health professionals, reflecting a shift in how sports organizations support athletes’ overall well-being. Murray’s death serves as a poignant reminder of the ongoing need for mental health awareness and support in the sporting community. (DW)
KEY ALZHEIMER’S STUDY RETRACTED OVER DATA MANIPULATION
In a significant development within Alzheimer’s disease research, a highly cited 2006 study in Nature by Karen Ashe and her team is being retracted due to image manipulation. The paper, which has been cited nearly 2,500 times, introduced the amyloid beta protein Aβ*56 as a potential cause of Alzheimer’s, influencing substantial subsequent research and funding. The retraction comes after allegations and an investigation into the first author, Sylvain Lesné, revealed manipulated data in this and other studies. Despite initial resistance from Ashe, who sought to address the issues through corrections, all authors except Lesné agreed to the retraction. This decision underscores ongoing debates about the amyloid hypothesis in Alzheimer’s research, especially in light of mixed results from therapies targeting amyloid proteins. The case highlights the complexities of scientific integrity, with calls for independent investigations into research misconduct to avoid conflicts of interest at institutions like the University of Minnesota, where Lesné remains a professor. (Science)
MICROSOFT AURORA AI REVOLUTIONIZES WEATHER POLLUTION FORECASTING
Microsoft has developed an AI model named Aurora that can forecast global weather and air pollution in less than a minute, a significant advancement in atmospheric science. This model is part of a new wave of AI-driven tools aimed at weather forecasting, with other contributions from Google DeepMind and Nvidia. Unlike traditional methods that combine machine learning with mathematical modeling, Aurora exclusively uses AI to predict air pollution, making it a pioneering effort in the field. The model efficiently predicts levels of six major air pollutants over a five-day period, using considerably less computational power than traditional models like those used by the Copernicus Atmosphere Monitoring Service. Aurora’s forecasts are comparable in quality to conventional models and are crucial for policymakers managing public health risks associated with air pollution. This breakthrough highlights the potential for AI to enhance weather and pollution forecasting with reduced computational demands, setting the stage for further innovative research in atmospheric chemistry and machine learning. (Nature)
T CRB STAR NEARS NOVA, EXPECTED TO OUTSHINE POLARIS
The star system T Coronae Borealis (T CrB), located 3,000 light years from Earth, is nearing the end of its 80-year cycle and is expected to exhibit a nova explosion soon. This event could occur anytime between now and the next few years, according to astronomers. T CrB consists of a red giant and a white dwarf, with the latter’s gravity pulling in gas from the red giant until enough accumulates to trigger a violent thermonuclear reaction. This process, repeating roughly every 80 years, causes the white dwarf to briefly shine as brightly as Polaris, the North Star. Novas like T CrB are critical for studying stellar behavior and the chemical properties of space, offering insights into phenomena like the origins of lithium in our solar system. While the exact timing of the nova is uncertain, it provides a unique observational opportunity for both professional astronomers and the general public, with visibility expected in the Corona Borealis constellation. (El Pais)
Thanks for reading. Let’s be careful out there.
WORDS: The Biology Guy.